NCT07657793 Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 164 participants in total. It began in 2026-06-07 with a primary completion date of 2027-09-30.

Brief Summary

The goal of this clinical trial is to learn if sirolimus, added to standard background therapy (corticosteroids and hydroxychloroquine), works to treat systemic lupus erythematosus-associated immune thrombocytopenia (SLE-ITP) in adults aged 18 to 65 years. The study also aims to evaluate the long-term effectiveness and safety of sirolimus over 48 weeks. The main questions it aims to answer are: 1. Does sirolimus increase the overall response rate (complete or partial remission of thrombocytopenia) at 24 weeks compared with placebo? 2. The safety issues when taking sirolimus over 24 weeks (Phase 1) and up to 48 weeks (Phase 2). 3. How long does the treatment effect last, and what is the relapse rate during open-label extension? In Phase 1 (first 24 weeks), researchers will compare sirolimus to a placebo (an identical-looking capsule containing no active drug) to see if sirolimus works to treat SLE-ITP when both groups also receive standardized prednisone and hydroxychloroquine. In Phase 2 (weeks 24 to 48), all participants will receive open-label sirolimus to assess long-term efficacy and safety. Participants will: 1. Phase 1: Take sirolimus (1.5 mg once daily) or a placebo for 24 weeks, plus standardized prednisone (tapered according to protocol) and hydroxychloroquine (0.4 g daily) 2. Phase 2: After completing Phase 1, take open-label sirolimus (1.5 mg once daily) for an additional 24 weeks, continuing stable or tapering doses of prednisone and hydroxychloroquine 3. Visit the clinic at screening, baseline, weeks 4, 12, 24 (end of Phase 1), and then at weeks 28, 36, and 48 (end of Phase 2) for checkups, blood tests, and disease activity assessments 4. Receive telephone follow-ups at weeks 8, 16, 20, 32, 40, and 44 to report platelet counts, medication adherence, and adverse events

Eligibility Criteria

Inclusion Criteria: Age ≥ 18 and \< 65 years 1. Meet 2012 SLICC or 2019 EULAR/ACR criteria for systemic lupus erythematosus 2. Meet ITP diagnostic criteria: platelet count ≤ 30×10\^9/L, or ≤ 50×10\^9/L with bleeding tendency 3. At least two CBC tests showing thrombocytopenia 4. Bone marrow smear showing megakaryocyte maturation disorder 5. Willing to sign informed consent form Exclusion Criteria: 1. Other causes of thrombocytopenia 2. Refractory SLE-ITP (no partial response after 3 months of high-dose steroids or immunosuppressants) 3. Use of rituximab within 6 months 4. Severe organ involvement (e.g., proteinuria \> 1g/24h, CNS involvement, cardiac/GI involvement) 5. Other autoimmune diseases (except Sjögren's syndrome) 6. Malignancy 7. Active infections (HIV, HBV, HCV, syphilis) 8. Severe liver or kidney dysfunction 9. Splenomegaly 10. Pregnancy or breastfeeding 11. Contraindications to study drugs 12. Unhealed major wounds or incisions 13. Judged unsuitable by investigator

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.